

Sinazid

Gliclazide

Composition

Sinazid Tablet: Each tablet contains Gliclazide BP 80 mg.

Description

Sinazid (Gliclazide) is a second generation sulfonylurea drug that has hypoglycemic and potentially useful hematological properties. It stimulates the release of insulin from pancreatic Beta cells by facilitating Ca^{+2} transport across the Beta cell membranes and decrease hepatic glucose output

Indication

Sinazid is indicated for the treatment of maturity onset diabetes mellitus (NIDDM) of patients who require oral antidiabetic treatment.

Dosage and Administration

Duration of action is 12 hour or more Adult: The initial dose is 40 to 50 mg daily, gradually increased if necessary up to 320 mg daily until adequate control is achieved. A single dose should not exceed 160 mg. When higher doses are required it should be taken twice daily and according to the main meals of the day. Elderly: Plasma clearance of Gliclazide is not altered in the elderly and steady state plasma levels are similar to those in adults under 65 years. Clinical experiences in the elderly shows that it is effective and well tolerated. Children: Gliclazide as with other sulfonylureas is not indicated for the treatment of juvenile onset diabetes mellitus.

Side Effects

There may be hypoglycemia in concurrent condition such as hepatic and renal disease, malnutrition, and alcohol intoxication. Sometime headache, gastrointestinal upsets, nausea, dizziness, skin reaction including rash, pruritis, Erythema may occur.

Contraindication

Gliclazide should not be used in Juvenile onset (Type-1) diabetes Diabetes associated with ketosis Patients having hypersensitivity for Sulfonylurea group of drugs Diabetic patients undergoing surgery, after severe injury or during infection Hepatic insufficiency Pregnant woman and lactating mother.

Use in Pregnancy and Lactation

Gliclazide is contraindicated in pregnant woman. It should not be used in breast feeding mother.

Drug interaction

The hypoglycemic effects of Gliclazide may be increased by aspirin, NSAIDs, Phenylbutazone, Sulfonamides, Cimetidine, Imidazole antifungal agents and monoamines oxidase inhibitors. The hypoglycemic effect of Gliclazide sometime may be reduced by Rifampicin, Barbiturates, Phenytoin, Thiazide diuretics, Diazoxide, Glucocorticosteroids, Estrogens, Sympathomimetic drugs and occasionally alcohol.

Overdosage

In accidental overdose, at first gastric lavage should be done and at the same time the hypoglycemia should be corrected. In severe cases IV infusion of 5% glucose should be started immediately with frequent monitoring of blood glucose and potassium level.

Presentation

Sinazid: Box containing 50 (5x10's) tablets in blister strips.

Manufactured by:

The IBN SINA Pharmaceutical Industry Ltd.
Shafipur, Gazipur, Bangladesh.

